Brain Advance Access originally published online on May 21, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brain, Vol. 126, No. 8, 1905-1912,
August 2003
© 2003 Guarantors of Brain
doi: 10.1093/brain/awg170
Minimum birth prevalence of mitochondrial respiratory chain disorders in children
1 The Murdoch Childrens Research Institute and 2 Genetic Health Services Victoria, Royal Childrens Hospital, 3 Department of Paediatrics, University of Melbourne, 4 Birth Defects Register, Public Health Division, Department of Human Services, Melbourne, Australia, and 5 Childrens Hospital, Innsbruck, Austria
Correspondence to: Dr. David R. Thorburn, The Murdoch Childrens Research Institute, Royal Childrens Hospital, Parkville 3052, Melbourne, Australia Email: thorburd{at}cryptic.rch.unimelb.edu.au
Mitochondrial respiratory chain disorders comprise a group of perhaps several hundred different genetic diseases. Each individual disorder is rare, but collectively they account for substantial use of health care resources. However, few accurate data on prevalence are available due to problems such as variation in clinical presentation, age of onset, referral practices and limitations of diagnostic methodologies. With this retrospective study, we aimed to determine the minimum birth prevalence of respiratory chain disorders that have onset in childhood, that is the proportion of births that will have onset of symptoms caused by a respiratory chain defect by 16 years of age. Of the 1 706 694 children born in the three south-eastern states of Australia (New South Wales, Victoria and South Australia) between January 1st 1987 and December 31st 1996, samples from 430 were referred for investigation of a respiratory chain disorder. Definite diagnosis of a respiratory chain disorder was made in 86 cases based on defined clinical, pathological, enzyme and molecular criteria. Age at presentation ranged from 0 to 129 months (median 4 months). The total data set predicts a minimum birth prevalence for respiratory chain disorders in children of 5.0/100 000 [95% confidence interval (CI) 4.06.2]. A significantly higher figure of 58.6/100 000 (95% CI 34.792.6) was noted for Australian families of Lebanese origin. Clinical awareness of respiratory chain disorders and investigation methods have improved since 1987, but not all affected children would have been recognized as such from the more recent years. The minimum birth prevalence of 6.2/100 000 (95% CI 4.58.4) for the 43 patients born between 1991 and 1994 is thought to be a more accurate estimate for respiratory chain disorders presenting in childhood. Combining our data with a previous study on prevalence of adult-onset respiratory chain disorders predicts a minimum birth prevalence of 13.1/100 000 or 1/7634 for respiratory chain disorders with onset at any age.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
R. J.R.J. Janssen, F. Distelmaier, R. Smeets, T. Wijnhoven, E. Ostergaard, N. G.J. Jaspers, A. Raams, S. Kemp, R. J.T. Rodenburg, P. H.M.G. Willems, et al. Contiguous gene deletion of ELOVL7, ERCC8 and NDUFAF2 in a patient with a fatal multisystem disorder Hum. Mol. Genet., September 15, 2009; 18(18): 3365 - 3374. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Haas, S. Parikh, M. J. Falk, R. P. Saneto, N. I. Wolf, N. Darin, and B. H. Cohen Mitochondrial Disease: A Practical Approach for Primary Care Physicians Pediatrics, December 1, 2007; 120(6): 1326 - 1333. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.-G. Debray, M. Lambert, I. Chevalier, Y. Robitaille, J.-C. Decarie, E. A. Shoubridge, B. H. Robinson, and G. A. Mitchell Long-term Outcome and Clinical Spectrum of 73 Pediatric Patients With Mitochondrial Diseases Pediatrics, April 1, 2007; 119(4): 722 - 733. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ostergaard, F. J. Hansen, N. Sorensen, M. Duno, J. Vissing, P. L. Larsen, O. Faeroe, S. Thorgrimsson, F. Wibrand, E. Christensen, et al. Mitochondrial encephalomyopathy with elevated methylmalonic acid is caused by SUCLA2 mutations Brain, March 1, 2007; 130(3): 853 - 861. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Scaglia, J. A. Towbin, W. J. Craigen, J. W. Belmont, E. O. Smith, S. R. Neish, S. M. Ware, J. V. Hunter, S. D. Fernbach, G. D. Vladutiu, et al. Clinical Spectrum, Morbidity, and Mortality in 113 Pediatric Patients With Mitochondrial Disease Pediatrics, October 1, 2004; 114(4): 925 - 931. [Abstract] [Full Text] [PDF] |
||||


